The observation that AhR inhibition increased the apoptosis rate of LNCaP and VCaP cells in vitro provided evidence that AhR inhibition represents a novel strategy for targeted therapy for prostatic cancer treatment. The gene discussed is AHR; the disease is prostate carcinoma.